Oppenheimer Initiates Coverage On Zura Bio with Outperform Rating, Announces Price Target of $17
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Justin Kim has initiated coverage on Zura Bio (NASDAQ:ZURA) with an Outperform rating and a price target of $17.
August 25, 2023 | 7:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zura Bio has been given an Outperform rating by Oppenheimer, with a price target of $17.
The Outperform rating from Oppenheimer indicates a positive outlook for Zura Bio. The price target of $17 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100